Special Considerations for the Child with Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2024

Overview

Journal Obes Pillars

Date 2024 Jul 2

PMID 38953014

Authors

Suzanne Cuda

Marisa Censani

Valerie OHara

Jennifer Paisley

Roohi Kharofa

Rushika Conroy

Brooke Sweeney

Cristina Fernandez

Meredith L Dreyer Gillette

Nancy T Browne

Affiliations

Soon will be listed here.

Abstract

Background: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details assessment and management of the child with overweight or obesity. The term "child" is defined as the child between 2 and 12 years of age. Because children are in a continual state of development during this age range, we will specify when our discussion applies to subsets within this age range. For the purposes of this CPS, we will use the following definitions: overweight in the child is a body mass index (BMI) ≥ 85th and <95th percentile, obesity in the child is a BMI ≥95th percentile, and severe obesity is a BMI ≥120% of the 95th percentile.

Methods: The information and clinical guidance in this OMA Clinical Practice Statement are based on scientific evidence, supported by medical literature, and derived from the clinical perspectives of the authors.

Results: This OMA Clinical Practice Statement provides an overview of prevalence of disease in this population, reviews precocious puberty in the child with obesity, discusses the current and evolving landscape of the use of anti-obesity medications in children in this age range, discusses the child with obesity and special health care needs, and reviews hypothalamic obesity in the child.

Conclusions: This OMA Clinical Practice Statement on the child with obesity is an evidence based review of the literature and an overview of current recommendations. This CPS is intended to provide a roadmap to the improvement of the health of children with obesity, especially those with metabolic, physiological, psychological complications and/or special healthcare needs. This CPS addresses treatment recommendations and is designed to help the clinician with clinical decision making.

References

Hu K, Staiano A . Trends in Obesity Prevalence Among Children and Adolescents Aged 2 to 19 Years in the US From 2011 to 2020. JAMA Pediatr. 2022; 176(10):1037-1039. PMC: 9315946. DOI: 10.1001/jamapediatrics.2022.2052. View

Freedman D, Mei Z, Srinivasan S, Berenson G, Dietz W . Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr. 2006; 150(1):12-17.e2. DOI: 10.1016/j.jpeds.2006.08.042. View

San Giovanni C, Sweeney B, Skelton J, Kelsey M, Kelly A . Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. J Clin Endocrinol Metab. 2021; 106(7):2103-2113. PMC: 8600003. DOI: 10.1210/clinem/dgab276. View

Wu X, Zhang Y, Lu M, Yu X, Ye X, Wang X . The Efficacy and Safety of Topiramate in the Prevention of Pediatric Migraine: An Update Meta-Analysis. Front Pediatr. 2020; 8:28. PMC: 7056737. DOI: 10.3389/fped.2020.00028. View

Matheson B, Colborn D, Bohon C . Bariatric Surgery in Children and Adolescents with Cognitive Impairment and/or Developmental Delay: Current Knowledge and Clinical Recommendations. Obes Surg. 2019; 29(12):4114-4126. DOI: 10.1007/s11695-019-04219-2. View

Pickering L, Jennum P, Gammeltoft S, Poulsgaard L, Feldt-Rasmussen U, Klose M . Sleep-wake and melatonin pattern in craniopharyngioma patients. Eur J Endocrinol. 2014; 170(6):873-84. DOI: 10.1530/EJE-13-1025. View

Yanovski J, Krakoff J, Salaita C, McDuffie J, Kozlosky M, Sebring N . Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011; 60(2):477-85. PMC: 3028347. DOI: 10.2337/db10-1185. View

Ahmet A, Blaser S, Stephens D, Guger S, Rutkas J, Hamilton J . Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab. 2006; 19(2):121-7. DOI: 10.1515/jpem.2006.19.2.121. View

Hoon D, Taylor M, Kapadia P, Gerhard T, Strom B, Horton D . Trends in Off-Label Drug Use in Ambulatory Settings: 2006-2015. Pediatrics. 2019; 144(4). PMC: 7286122. DOI: 10.1542/peds.2019-0896. View

10.

Lustig R, Hinds P, Ringwald-Smith K, Christensen R, Kaste S, Schreiber R . Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003; 88(6):2586-92. DOI: 10.1210/jc.2002-030003. View

11.

Huang A, Reinehr T, Roth C . Connections Between Obesity and Puberty: Invited by Manuel Tena-Sempere, Cordoba. Curr Opin Endocr Metab Res. 2020; 14:160-168. PMC: 7543977. DOI: 10.1016/j.coemr.2020.08.004. View

12.

Srivastava G, Fox C, Kelly A, Jastreboff A, Browne A, Browne N . Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. Obesity (Silver Spring). 2019; 27(2):190-204. PMC: 6449849. DOI: 10.1002/oby.22385. View

13.

Danielsson P, Svensson V, Kowalski J, Nyberg G, Ekblom O, Marcus C . Importance of age for 3-year continuous behavioral obesity treatment success and dropout rate. Obes Facts. 2012; 5(1):34-44. DOI: 10.1159/000336060. View

14.

Borzutzky C, King E, Fox C, Stratbucker W, Tucker J, Yee J . Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: Data from the POWER Work Group. Pediatr Obes. 2020; 16(1):e12701. DOI: 10.1111/ijpo.12701. View

15.

Mamun A, Mannan M, Doi S . Gestational weight gain in relation to offspring obesity over the life course: a systematic review and bias-adjusted meta-analysis. Obes Rev. 2013; 15(4):338-47. DOI: 10.1111/obr.12132. View

16.

McCandless S, Yanovski J, Miller J, Fu C, Bird L, Salehi P . Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017; 19(12):1751-1761. PMC: 5673540. DOI: 10.1111/dom.13021. View

17.

Ling J, Chen S, Zahry N, Kao T . Economic burden of childhood overweight and obesity: A systematic review and meta-analysis. Obes Rev. 2022; 24(2):e13535. PMC: 10078467. DOI: 10.1111/obr.13535. View

18.

Chawner L, Blundell-Birtill P, Hetherington M . Interventions for Increasing Acceptance of New Foods Among Children and Adults with Developmental Disorders: A Systematic Review. J Autism Dev Disord. 2019; 49(9):3504-3525. PMC: 6667424. DOI: 10.1007/s10803-019-04075-0. View

19.

Czepiel K, Perez N, Reyes K, Sabharwal S, Stanford F . Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US. Front Endocrinol (Lausanne). 2020; 11:290. PMC: 7237714. DOI: 10.3389/fendo.2020.00290. View

20.

Weghuber D, Barrett T, Barrientos-Perez M, Gies I, Hesse D, Jeppesen O . Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022; 387(24):2245-2257. PMC: 9997064. DOI: 10.1056/NEJMoa2208601. View